AVE 3247

Drug Profile

AVE 3247

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Anti-ischaemics; Antithrombotics
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Thrombosis

Most Recent Events

  • 23 May 2006 Phase-I clinical trials in Thrombosis in France (unspecified route)
  • 01 Mar 2005 Preclinical trials in Thrombosis in USA (unspecified route)
  • 01 Mar 2005 Preclinical trials in Thrombosis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top